Presenting at the 2022 AAN Annual Meeting, Mayo Clinic researchers investigated and compared the survival rates and symptoms of Parkinson disease and Parkinson disease psychosis.
Presenting at the 2022 AAN Annual Meeting, researchers examined pimavanserin for the treatment of dementia-related psychosis.
Researchers sought to determine the effect GBA variants have on cognitive status in patients with amyotrophic lateral sclerosis.
Male mice were exposed to chronic stress using a social defeat stress experiment. Mice were assessed for behavioral deviations and impacts to motor learning after the stress experiment as well as neural changes due to stress.
All individuals in the study who died between 2017 and 2019 due to sporadic Creutzfeldt-Jakob disease (sCJD) and controls who had alternative neuropathological diagnoses were assessed for sCJD using the original and revised diagnostic criteria.
L-DOPA is the frontline therapy for patients with PD, however, as the disease progresses, patients require higher and more frequent dosing. In order to better understand the binding affinity of L-DOPA and associated metabolites, binding affinity and surface plasmon resonance experiments were performed.
Authors of this study collected data between June 2020 and June 2021 using a 3-part electronic questionnaire oral health quality of life in those with Parkinson disease.
The FDA approved Dhivy in November 2021 based upon bioavailability studies comparing Dhivy to an immediate-release tablet containing 25mg of carbidopa and 100mg of levodopa.
People with myocardial infarction (MI) have a reduced risk for Parkinson disease and secondary parkinsonism during a median follow-up of 21 years.
Higher flavonoid intake is associated with a reduced risk for mortality in patients with Parkinson disease (PD).
